Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
出版年份 2022 全文链接
标题
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
作者
关键词
-
出版物
Cancers
Volume 14, Issue 4, Pages 1022
出版商
MDPI AG
发表日期
2022-02-18
DOI
10.3390/cancers14041022
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antibody–drug conjugates in solid tumors: a look into novel targets
- (2021) Carmen Criscitiello et al. Journal of Hematology & Oncology
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- (2021) Chiara Corti et al. Cancers
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
- (2020) Jonathan Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiemetics: ASCO Guideline Update
- (2020) Paul J. Hesketh et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–Drug Conjugates: The Last Decade
- (2020) Nicolas Joubert et al. Pharmaceuticals
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Study of the Effect of Dietary Counseling During Adjuvant Chemotherapy on Chemotherapy Induced Nausea and Vomiting, and Quality of Life in Patients With Breast Cancer
- (2018) Safa Najafi et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
- (2017) Steven Grunberg Cancer Control
- 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
- (2016) F. Roila et al. ANNALS OF ONCOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey
- (2015) Cheryl Vidall et al. SUPPORTIVE CARE IN CANCER
- Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis
- (2013) Camilo Rojas et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Factors affecting patient's perception of anticancer treatments side-effects: an observational study
- (2013) Stefania Russo et al. Expert Opinion On Drug Safety
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
- (2010) M. Aapro et al. ANNALS OF ONCOLOGY
- Anticipatory nausea and vomiting
- (2010) Joseph A. Roscoe et al. SUPPORTIVE CARE IN CANCER
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
- (2010) Luigi Celio et al. SUPPORTIVE CARE IN CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now